SeaStar Medical Reports 65.1% 90-Day Survival in Pediatric AKI Study
SeaStar Medical said its QUELIMMUNE treatment showed 65.1% 90-day survival in a pediatric acute kidney injury study.
Related stories
TransAlta shares rise 7.7% as net earnings turn positive
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
IPG Photonics Reports Third-Quarter 2026 Revenue of $287.5 Million
Revenue rose 15% year over year and exceeded FactSet estimates of $283.3 million. Adjusted EPS was $0.61 versus consensus of $0.49. IPG guided to fourth-quarter revenue of $265 mil
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
DigitalOcean Reports Q3 Revenue of $321 Million, Raises 2026 Outlook
Third-quarter revenue rose 40% year over year to $321 million; adjusted EPS was $0.45 versus FactSet consensus of $0.32. The company guided fourth-quarter revenue to $348 million–$
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
Ball shares fall about 5% as company swings to Q3 loss
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
Aehr Test Systems shares jump 14.6% after Q1 results beat
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
S&P 500 and Nasdaq Open Higher as Oil Prices Extend Declines
U.S. stocks opened higher as oil prices extended their declines, with midterm elections on the agenda.
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC